Cholesterol Absorption Inhibitor - Pipeline Insight, 2019 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Feb 8, 2019--The “Cholesterol Absorption Inhibitor - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.
Cholesterol Absorption Inhibitor - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cholesterol Absorption Inhibitor development.
The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
Scope of the ReportProvides a snapshot of the therapeutics pipeline activity for Cholesterol Absorption Inhibitor Features the Cholesterol Absorption Inhibitor pipeline across the complete product development cycle including all clinical and non-clinical stages Offers detailed therapeutic product profiles of Cholesterol Absorption Inhibitor with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration Coverage of dormant and discontinued pipeline projects across Cholesterol Absorption Inhibitor
Reasons to BuyEstablish a comprehensive understanding of the current pipeline scenario across Cholesterol Absorption Inhibitor to formulate effective R&D strategies Assess challenges and opportunities that influence Cholesterol Absorption Inhibitor research & development (R&D) Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage Identify and understand the sought after therapy areas and indications for Cholesterol Absorption Inhibitor Identify the product attributes and use it for target finding, drug repurposing, and precision medicine Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for Cholesterol Absorption Inhibitor to enhance and expand business potential and scope Plan prospective mergers and acquisitions effectively by identifying key players in this area and their most promising pipeline therapeutics and developmental progress
1. Report Introduction
2. Cholesterol Absorption Inhibitor - Overview
3. Pipeline TherapeuticsAn Overview of Pipeline Products for Cholesterol Absorption Inhibitor
4. Comparative Analysis
5. Cholesterol Absorption Inhibitor Pipeline Products in Clinical StagesProduct Description Research and Development Product Development Activities
6. Cholesterol Absorption Inhibitor Pipeline Products in Non-clinical StagesProduct Description Research and Development Product Development Activities
7. Therapeutic Assessment: Active ProductsPipeline Assessment by Route of Administration Pipeline Assessment by Stage and Route of Administration Pipeline Assessment by Molecule Type Pipeline Assessment by Stage and Molecule Type
8. Inactive Pipeline ProductsProduct Description Research and Development Product Development Activities Reason for dormancy/discontinuation
Companies MentionedSchering-Plough Kotobuki Pharmaceutical Lipideon Biotechnology AG AstraZeneca AtheroNova Esperion Therapeutics Zhejiang Hisun Pharmaceutical Merck DreamPharma Corporation
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/grnb7l/cholesterol?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20190208005266/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Cardiovascular Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 02/08/2019 09:03 AM/DISC: 02/08/2019 09:03 AM